BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,249,402,319 | -16.6% | 18,354,669 | -0.0% | 0.03% | -13.9% |
| Q2 2023 | $1,498,442,320 | +9.6% | 18,356,515 | -0.4% | 0.04% | +2.9% |
| Q1 2023 | $1,367,429,498 | -9.3% | 18,431,453 | +1.3% | 0.04% | -14.6% |
| Q4 2022 | $1,508,368,924 | +18.3% | 18,199,432 | +305.5% | 0.04% | +10.8% |
| Q3 2022 | $1,274,520,000 | -17.6% | 4,487,742 | +0.6% | 0.04% | -14.0% |
| Q2 2022 | $1,546,134,000 | -19.7% | 4,460,345 | +0.3% | 0.04% | -6.5% |
| Q1 2022 | $1,924,978,000 | -15.9% | 4,445,265 | +0.4% | 0.05% | -11.5% |
| Q4 2021 | $2,290,077,000 | +8.2% | 4,426,638 | +1.4% | 0.05% | -1.9% |
| Q3 2021 | $2,115,791,000 | +25.9% | 4,366,328 | +17.0% | 0.05% | +26.2% |
| Q2 2021 | $1,680,902,000 | +18.6% | 3,733,181 | +0.6% | 0.04% | +10.5% |
| Q1 2021 | $1,417,786,000 | +24.3% | 3,712,162 | +3.4% | 0.04% | +15.2% |
| Q4 2020 | $1,140,435,000 | +30.9% | 3,591,352 | +2.2% | 0.03% | +13.8% |
| Q3 2020 | $870,903,000 | -8.8% | 3,515,534 | -2.8% | 0.03% | -14.7% |
| Q2 2020 | $955,217,000 | +38.2% | 3,617,289 | -0.8% | 0.03% | +17.2% |
| Q1 2020 | $691,114,000 | -11.8% | 3,644,728 | +2.1% | 0.03% | +7.4% |
| Q4 2019 | $783,388,000 | +12.4% | 3,568,802 | +0.2% | 0.03% | +3.8% |
| Q3 2019 | $697,176,000 | -4.8% | 3,563,026 | +1.4% | 0.03% | -7.1% |
| Q2 2019 | $732,332,000 | +5.6% | 3,512,553 | +0.6% | 0.03% | +3.7% |
| Q1 2019 | $693,529,000 | +39.2% | 3,492,964 | +1.4% | 0.03% | +22.7% |
| Q4 2018 | $498,379,000 | -27.4% | 3,443,749 | +2.4% | 0.02% | -18.5% |
| Q3 2018 | $686,101,000 | +41.2% | 3,361,425 | +2.4% | 0.03% | +35.0% |
| Q2 2018 | $485,838,000 | +0.4% | 3,283,799 | +2.5% | 0.02% | -4.8% |
| Q1 2018 | $483,679,000 | +18.7% | 3,202,334 | +1.8% | 0.02% | +16.7% |
| Q4 2017 | $407,455,000 | +8.8% | 3,145,154 | +1.5% | 0.02% | 0.0% |
| Q3 2017 | $374,642,000 | +4.8% | 3,099,031 | +1.9% | 0.02% | 0.0% |
| Q2 2017 | $357,489,000 | +17.0% | 3,042,458 | +1.2% | 0.02% | +12.5% |
| Q1 2017 | $305,528,000 | +3.5% | 3,005,690 | +4.7% | 0.02% | 0.0% |
| Q4 2016 | $295,282,000 | -3.4% | 2,871,552 | +2.8% | 0.02% | -11.1% |
| Q3 2016 | $305,760,000 | -1.4% | 2,792,325 | +1.6% | 0.02% | -5.3% |
| Q2 2016 | $310,083,000 | +22.5% | 2,749,702 | +2.6% | 0.02% | +18.8% |
| Q1 2016 | $253,194,000 | +8.0% | 2,678,730 | +2.8% | 0.02% | 0.0% |
| Q4 2015 | $234,414,000 | -71.3% | 2,604,595 | -81.7% | 0.02% | -48.4% |
| Q3 2015 | $818,095,000 | +230.9% | 14,212,040 | +466.0% | 0.03% | +82.4% |
| Q2 2015 | $247,265,000 | +0.9% | 2,511,062 | +2.8% | 0.02% | 0.0% |
| Q1 2015 | $244,950,000 | +14.0% | 2,442,423 | +5.0% | 0.02% | +13.3% |
| Q4 2014 | $214,918,000 | – | 2,325,955 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |